# V-IMMUNE® for Immune Thrombocytopenia

> **NCT06962631** · PHASE3 · RECRUITING · sponsor: **On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.** · enrollment: 31 (estimated)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **BIOLOGICAL:** 5% (5g/100 ml) intravenous immunoglobin

## Key facts

- **NCT ID:** NCT06962631
- **Lead sponsor:** On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-18
- **Primary completion:** 2026-08-27
- **Final completion:** 2027-02-27
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06962631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06962631, "V-IMMUNE® for Immune Thrombocytopenia". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06962631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*